Maryland Tech Journal
SEE OTHER BRANDS

Get your science and technology news from Maryland

Maryland Tech Journal: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Maryland Tech Journal.

Press releases published on June 20, 2025

Euroopan lääkeviraston ihmislääkekomitealta (CHMP) myönteinen lausunto darolutamidin kolmannelle käyttöaiheelle edennyttä eturauhassyöpää sairastavien potilaiden hoidossa

Euroopan lääkeviraston ihmislääkekomitealta (CHMP) myönteinen lausunto darolutamidin kolmannelle käyttöaiheelle edennyttä eturauhassyöpää sairastavien potilaiden hoidossa

ORION OYJ LEHDISTÖTIEDOTE 20.6.2025 klo 13.30          Euroopan lääkeviraston ihmislääkekomitealta (CHMP) myönteinen lausunto darolutamidin kolmannelle käyttöaiheelle edennyttä eturauhassyöpää sairastavien potilaiden hoidossa CHMP suosittaa myyntiluvan …

Ipsen receives positive CHMP opinion for Cabometyx® in previously treated advanced neuroendocrine tumors

Ipsen receives positive CHMP opinion for Cabometyx® in previously treated advanced neuroendocrine tumors

If approved, Cabometyx® would be the first and only systemic therapy approved in the European Union for previously treated neuroendocrine tumors, regardless of tumor site, grade or previous non-somatostatin analogue-based systemic therapy1,2 Recommendation …

Ipsen reçoit un avis positif du CHMP pour Cabometyx® dans les tumeurs neuroendocrines avancées précédemment traitées

Ipsen reçoit un avis positif du CHMP pour Cabometyx® dans les tumeurs neuroendocrines avancées précédemment traitées

S’il est approuvé, Cabometyx® sera le premier et unique traitement systémique autorisé dans l’Union européenne pour les tumeurs neuroendocrines précédemment traitées, indépendamment de la localisation de la tumeur, de sa gravité et de l’administration ou …

MAIV Announces Strategic Investment and Advisory Partnership with Covey

MAIV Announces Strategic Investment and Advisory Partnership with Covey

BERLIN, June 20, 2025 (GLOBE NEWSWIRE) -- MAIV, the on-chain platform for private equity deals, is proud to announce a strategic investment and advisory partnership with Covey, a web3-native firm specializing in advisory, capital, development, and …

PAIRMiners baut globale Cloud-Mining-Dienste aus, da XRP- und DOGE-Investoren nach Stabilität suchen

PAIRMiners baut globale Cloud-Mining-Dienste aus, da XRP- und DOGE-Investoren nach Stabilität suchen

Die Plattform unterstützt automatische tägliche Auszahlungen und Mining in mehreren Währungen in über 180 Ländern Bild von PAIRMiner BERLIN, June 20, 2025 (GLOBE NEWSWIRE) -- Angesichts der anhaltenden Volatilität auf dem Kryptomarkt wenden sich Anleger, …

VdoCipher Blocks Over 250,000 Video Piracy Attempts in Just 12 Months with New Detection Engine

VdoCipher Blocks Over 250,000 Video Piracy Attempts in Just 12 Months with New Detection Engine

GURUGRAM, India, June 20, 2025 (GLOBE NEWSWIRE) -- In a significant step toward securing online video content, VdoCipher has announced the success of its newly deployed Pirate Detection Engine, which has blocked over 250,000 piracy attempts in just the …

NurExone Advances U.S. Growth Strategy with Acceptance into Prestigious ARMI HealthTech Hub Accelerator and Provides Corporate Update

NurExone Advances U.S. Growth Strategy with Acceptance into Prestigious ARMI HealthTech Hub Accelerator and Provides Corporate Update

TORONTO and HAIFA, Israel, June 20, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a biotech company developing exosome-based therapies for central nervous system injuries, announced …

Dupixent® (dupilumab) Approved in the U.S. as the Only Targeted Medicine to Treat Patients with Bullous Pemphigoid (BP)

Dupixent® (dupilumab) Approved in the U.S. as the Only Targeted Medicine to Treat Patients with Bullous Pemphigoid (BP)

Approval based on pivotal results showing improvements in sustained disease remission and reductions in itch and oral corticosteroid use compared to placebo in adults with BP BP is a chronic, debilitating and relapsing rare skin disease affecting …

Press Release: Dupixent approved in the US as the only targeted medicine to treat patients with bullous pemphigoid

Press Release: Dupixent approved in the US as the only targeted medicine to treat patients with bullous pemphigoid

Dupixent approved in the US as the only targeted medicine to treat patients with bullous pemphigoid Approval based on pivotal results showing improvements in sustained disease remission and reductions in itch and oral corticosteroid use compared to placebo …

Communiqué de presse : Dupixent est approuvé aux États-Unis comme le seul médicament ciblé pour traiter les patients atteints de pemphigoïde bulleuse

Communiqué de presse : Dupixent est approuvé aux États-Unis comme le seul médicament ciblé pour traiter les patients atteints de pemphigoïde bulleuse

Dupixent est approuvé aux États-Unis comme le seul médicament ciblé pour traiter les patients atteints de pemphigoïde bulleuse L’approbation est basée sur des résultats pivots montrant des améliorations de la rémission durable de la maladie et une …

Translr App Announces New Strategies to Help Reduce Gender Disclosure Anxiety for Transgender Users

Translr App Announces New Strategies to Help Reduce Gender Disclosure Anxiety for Transgender Users

New York, New York, June 19, 2025 (GLOBE NEWSWIRE) -- As debates around gender history disclosure continue to spark controversy in public discourse and on mainstream dating platforms, Translr announces new strategies aimed at reducing gender disclosure …

Telix Theranostic Programs and Satellite Symposia on Innovation in PSMA and CAIX Imaging Featured at SNMMI 2025

Telix Theranostic Programs and Satellite Symposia on Innovation in PSMA and CAIX Imaging Featured at SNMMI 2025

MELBOURNE, Australia and INDIANAPOLIS, June 20, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”, “the Company”) today announces five abstract presentations and two satellite symposia featuring its developmental …

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms of Service